TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

Research output: Contribution to journalReviewResearchpeer-review

Dorte X Gram, Jens J Holst, Arpad Szallasi

With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.

Original languageEnglish
JournalTrends in Molecular Medicine
Issue number11
Pages (from-to)1002-1013
Number of pages12
Publication statusPublished - Nov 2017

    Research areas

  • Journal Article, Review

ID: 189623760